212 related articles for article (PubMed ID: 27902601)
1. Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer.
Louvet C; De Bellis A; Pereira B; Bournaud C; Kelly A; Maqdasy S; Roche B; Desbiez F; Borson-Chazot F; Tauveron I; Batisse-Lignier M
Medicine (Baltimore); 2016 Nov; 95(48):e5474. PubMed ID: 27902601
[TBL] [Abstract][Full Text] [Related]
2. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
4. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.
Moleti M; Violi MA; Montanini D; Trombetta C; Di Bella B; Sturniolo G; Presti S; Alibrandi A; Campennì A; Baldari S; Trimarchi F; Vermiglio F
J Clin Endocrinol Metab; 2014 May; 99(5):1783-9. PubMed ID: 24432992
[TBL] [Abstract][Full Text] [Related]
6. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
8. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
9. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
Li HX; Xiang N; Hu WK; Jiao XL
J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
[TBL] [Abstract][Full Text] [Related]
10. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
11. Euthyroid Graves' orbitopathy and incidental papillary thyroid microcarcinoma.
Melcescu E; Horton WB; Pitman KT; Vijayakumar V; Koch CA
Hormones (Athens); 2013; 12(2):298-304. PubMed ID: 23933699
[TBL] [Abstract][Full Text] [Related]
12. Treating the thyroid in the presence of Graves' ophthalmopathy.
Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
[TBL] [Abstract][Full Text] [Related]
13. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study.
Watanabe N; Noh JY; Kozaki A; Iwaku K; Sekiya K; Kosuga Y; Matsumoto M; Suzuki M; Yoshihara A; Ohye H; Kobayashi S; Kunii Y; Mukasa K; Sugino K; Inoue T; Ito K
J Clin Endocrinol Metab; 2015 Jul; 100(7):2700-8. PubMed ID: 25965082
[TBL] [Abstract][Full Text] [Related]
15. Unusual case of radioactive iodine-induced Graves' disease with orbitopathy following total thyroidectomy in a patient with papillary thyroid microcarcinoma.
Zgubieński K; Walczyk A; Kowalska A
Endokrynol Pol; 2020; 71(3):277-278. PubMed ID: 32293702
[TBL] [Abstract][Full Text] [Related]
16. Total thyroid ablation in Graves' orbitopathy.
Menconi F; Leo M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Aug; 38(8):809-15. PubMed ID: 25740065
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
[TBL] [Abstract][Full Text] [Related]
18. A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy.
Aoyama M; Takizawa H; Tsuboi M; Nakagawa Y; Tangoku A
Endocr J; 2017 Dec; 64(12):1143-1147. PubMed ID: 28883260
[TBL] [Abstract][Full Text] [Related]
19. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
[TBL] [Abstract][Full Text] [Related]
20. Graves' disease and thyroid cancer.
Behar R; Arganini M; Wu TC; McCormick M; Straus FH; DeGroot LJ; Kaplan EL
Surgery; 1986 Dec; 100(6):1121-7. PubMed ID: 3787468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
